AMLX FY 2020 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$650,000-54.4% YoY

Gross Profit

-$24M-3683.7% margin

Operating Income

-$39M-6000.8% margin

Net Income

-$42M-6504.6% margin

EPS (Diluted)

$-0.79

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$243,000

Balance Sheet

Total Assets

$14M

Total Liabilities

$81M

Stockholders' Equity

-$67M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$650,000	$1M	-54.4%
Gross Profit	-$24M	-$10M	-128.6%
Operating Income	-$39M	-$14M	-187.8%
Net Income	-$42M	-$15M	-185.4%